Jonathan J. Mazelsky
Net Worth
Last updated:
What is Jonathan J. Mazelsky net worth?
The estimated net worth of Mr. Jonathan J. Mazelsky is at least $136,366,317 as of 5 Aug 2024. He owns shares worth $50,459,891 as insider, has earned $55,426,426 from insider trading and has received compensation worth at least $30,480,000 in IDEXX Laboratories, Inc..
What is the salary of Jonathan J. Mazelsky?
Mr. Jonathan J. Mazelsky salary is $2,540,000 per year as Pres, Chief Executive Officer & Director in IDEXX Laboratories, Inc..
How old is Jonathan J. Mazelsky?
Mr. Jonathan J. Mazelsky is 64 years old, born in 1961.
What stocks does Jonathan J. Mazelsky currently own?
As insider, Mr. Jonathan J. Mazelsky owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
IDEXX Laboratories, Inc. (IDXX) | Pres, Chief Executive Officer & Director | 79,246 | $636.75 | $50,459,891 |
What does IDEXX Laboratories, Inc. do?
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Jonathan J. Mazelsky insider trading
IDEXX Laboratories, Inc.
Mr. Jonathan J. Mazelsky has made 27 insider trades between 2013-2024, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 27,992 units of IDXX stock on 4 Nov 2019. As of 5 Aug 2024 he still owns at least 79,246 units of IDXX stock.
IDEXX Laboratories key executives
IDEXX Laboratories, Inc. executives and other stock owners filed with the SEC:
- Mr. Brian P. McKeon (63) Chief Financial Officer, Executive Vice President & Treasurer
- Mr. James F. Polewaczyk (61) Executive Vice President & Chief Commercial Officer
- Mr. Jonathan J. Mazelsky (64) Pres, Chief Executive Officer & Director
- Mr. Jonathan W. Ayers (69) Senior Advisor & Director
- Mr. Michael J. Lane (57) Executive Vice President and GM of Reference Laboratories & Information Technology
- Ms. Sharon E. Underberg (64) Senior Vice President, Gen. Counsel & Corporation Sec.